Today Biogen Idec (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback